Applying Proteogenomics to Characterize Molecular Features Associated With a High‐Risk HOXB13 Gene Variant in Prostate Cancer Tumors
Year: 2026
Type: article
Study design: Observational Study
Abstract: ABSTRACT The rare HOXB13 G84E variant is one of few established high‐risk prostate cancer (PrCa) variants, yet the underlying molecular mechanisms by which it drives tumor development remain unknown. Prostate tumors from six heterozygous G84E variant carriers and 18 non‐carriers (wild‐type) were examined using the Human AmpliSeq Transcriptome Gene Expression Panel, and proteomes were generated by mass spectrometry (SWATH). We identified a 799‐gene expression profile and a 75‐protein expression profile in G84E‐positive tumors when compared with wild‐type tumors. Cluster analysis revealed a top‐ranked 23 protein profile, which mapped to lipogenesis pathways. Integration of transcriptome and proteome data revealed overlapping differential expression of three genes ( NCLN , NFIB , and VASN ), two of which have an established link to lipid metabolic pathways. Examination of publicly available transcriptome data from 493 primary PrCa tumors from the The Cancer Genome Atlas (TCGA) tumors revealed 52 tumors with a similar differential expression profile for these three genes. Herein, an innovative proteogenomic approach was used to map molecular changes unique to HOXB13 perturbation in prostate tumors, revealing upregulation of genes in the steroid metabolic, lipid biosynthesis, and fatty acid metabolic pathways.
Source: MedComm
DOI: 10.1002/mco2.71078
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,500
Funders: Children's Medical Research, Mazda Foundation, Royal Hobart Hospital Research Foundation, David and Elaine Potter Foundation, Australian Government, Australian Cancer Research Foundation, Ian Potter Foundation, Cancer Australia, Cancer Institute NSW, University of Tasmania, University of Sydney, NSW Ministry of Health, Tasmanian Community Fund, Tour de Cure, Australian Research Council, National Health and Medical Research Council, Cancer Council NSW, Cancer Council Tasmania, National Cancer Institute
OpenAlex ID: W7223092968
